Stromal Caveolin-1 and Caveolin-2 Expression in Primary Tumors and Lymph Node Metastases

Table 1

Correlation between caveolin-1 expression in lung cancer stroma and clinical parameters.

	Total	Negative		Weak		Strong		value
	n	n	%	n	%	n	%
All	147	53	36.1	42	28.5	52	35.4
Sex								0.25
Female	27	6	22.2	9	33.3	12	44.5
Male	120	47	39.2	33	27.5	40	33.3
Age								0.79
<MW	59	22	37.3	18	30.5	19	32.2
>MW	83	30	36.1	22	26.5	31	37.4
n.a.	5
Histology								<0.01
SCC	69	17	24.6	17	24.7	35	50.7
AC	53	29	54.7	16	30.2	8	15.1
LCLC	9	3	33.3	1	11.1	5	55.6
Others	16	4	25.0	8	50.0	4	25.0
Grade combined								0.79
G1 + 2	66	22	33.3	21	31.8	23	34.9
G3 + 4	73	28	38.4	20	27.4	25	34.2
n.a.	8
Tumor size								0.17
pT1	30	10	33.3	13	43.4	7	23.3
pT2	86	31	36.1	21	24.4	34	39.5
pT3	21	9	42.9	3	14.2	9	42.9
pT4	8	3	37.5	4	50.0	1	12.5
n.a.	2
Lymph node status								0.09
pN0	76	32	42.1	22	29.0	22	28.9
pN1	41	9	22.0	15	36.6	17	41.4
pN2 + 3	28	12	42.9	4	14.3	12	42.9
n.a.	2
Distant metastasis								0.26
pM0	136	47	35.6	39	28.7	50	36.7
pM1	9	5	55.6	3	33.3	1	11.1
n.a.	2
UICC stage								0.10
IA + B	70	29	41.4	21	30.0	20	28.6
IIA + B	31	6	19.4	11	35.4	14	45.2
IIIA+B	34	12	35.3	6	17.6	16	47.1
IV	9	5	55.6	3	33.3	1	11.1
n.a.	3
Death								0.74
No	37	12	32.4	10	27.0	15	40.6
Yes	107	40	37.4	31	29.0	36	33.6
n.a.	3
Smoking								0.99
Current	66	23	34.9	20	30.3	23	34.8
Ex-smoker	63	24	38.1	20	31.7	19	30.2
Never	3	1	33.3	1	33.3	1	33.3
n.a.	15
Asbestos exposure								0.18
Exposed	42	20	47.6	10	23.8	12	28.6
Nonexposed	90	28	31.1	30	33.3	32	35.6
n.a.	15

n.a.: not available; ex-smoker: quit smoking > 6 months prior to surgery.